A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT02760485. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Phase 1/2 Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study identification
- NCT ID
- NCT02760485
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Interventions
- ibrutinib Drug
- itacitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 28, 2016
- Primary completion
- Jun 5, 2022
- Completion
- Jun 5, 2022
- Last update posted
- Jun 14, 2023
2016 – 2022
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital | Los Angeles | California | 90033 | — |
| Moores UC San Diego Cancer Center | San Diego | California | 92093 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Georgia Regents Research Institute | Augusta | Georgia | 30912 | — |
| University of Maryland Cancer Center | Baltimore | Maryland | 21201 | — |
| University of Michigan Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Michigan State University Breslin Cancer Center | Lansing | Michigan | 48910 | — |
| St Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Comprehensive Cancer Center of Nevada | Las Vegas | Nevada | 89169 | — |
| Regional Cancer Center Associates, LLC | Little Silver | New Jersey | 07739 | — |
| Roswell Cancer Center | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Toledo Clinic Cancer Centers | Toledo | Ohio | 43623 | — |
| Tulsa Cancer Center | Tulsa | Oklahoma | 74146 | — |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | — |
| University of Pennsylvania Health System | Philadelphia | Pennsylvania | 19104 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| Northwest Medical Specialists & Research Institute | Puyallup | Washington | 98373 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02760485, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02760485 live on ClinicalTrials.gov.